Entities

Schrödinger director with corporate communications and advisory experience. Previously led global communications at SoftBank and held leadership roles at Time Warner and News Corporation.

Schrödinger board chairman since October 2018. Previously led Sony Entertainment and Sony Pictures Entertainment and has media, technology and company governance experience.

Steven Price founded company-building and investment firm 25madison and previously served as a US deputy assistant secretary of defense. Protego publishes him as an adviser.

Provides cardiac safety testing and drug discovery services using its CellOPTIQ platform to measure electrical activity, calcium handling and contraction in human-derived cardiomyocytes.

Develops engineered T-cell therapies for cancer, using its lateral CAR architecture to improve the performance of cellular immunotherapies.

Develops cancer immunotherapies that target macrophages in the tumor microenvironment, seeking to alter immune cell activity and improve antitumor responses.

Develops oncolytic virus therapies for cancer, using phenotypic screening to select viruses that kill cancer cells and stimulate antitumor immune responses.

Develops nanoparticle-based medicines intended to establish antigen-specific immune tolerance in the liver for autoimmune and immune-mediated diseases.

Martin Diggle co-founded Vulpes and chairs its UK company. His biography also identifies him as chairman and director of the Life Sciences fund. He has more than twenty years of life-sciences investment experience and has served on boards including Oxford Biomedica, Scancell, Proteome Sciences, Chronos, Leucid and Oxford Endovascular. Previously he worked at UBS/Brunswick and Morgan Stanley. He studied Philosophy, Politics and Economics at Oxford. Personal capital and institutional purchases are distinct.

Michael Wacker joined Biomed in 2019 and is currently listed as managing partner with both BioMedPartners and BiomedVC. He co-founded vaccine developer GlycoVaxyn, later acquired by GSK, and previously held leadership roles at Polyneuron and Inositec. His training includes biochemistry and microbiology at ETH Zurich. These are institutional manager affiliations; no personal portfolio investment is inferred.

Invests in early-stage companies developing science and engineering-based technologies for healthcare, climate and energy. It provides seed and Series A capital, follow-on financing and operational support to help Indian deep tech startups build commercial businesses.

Brain-health software company using smartphone typing patterns and machine learning to generate measures of cognitive performance. Its Skye application collects keystroke behavior rather than typed content and provides personal metrics and trends for brain-health monitoring and research.

David Cummings is publicly named by Cambridge Angels in its selected individual-member directory. Membership is an angel-network affiliation: individual investment choices are independent, and membership alone does not prove personal investment in any portfolio company.

Estelle Mamane appears in Idinvest Partners’ August2020 primary directory as Investor Relations Europe. The role belonged to the historical European investment manager’s published investment, investor-relations or corporate support platform, spanning venture/growth, private debt and dedicated portfolios. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.

Franco Danesi is a Black Opal venture partner. Its published career summary identifies venture investing and investment management, investment-banking experience at Goldman Sachs and Morgan Stanley and London Business School education. The embedded metadata misspells his surname as Daneis; the displayed biography and current team identify Danesi, matching the preserved existing person.

Jonathan Userovici appears in Idinvest Partners’ August2020 primary directory as Investment Manager. The role belonged to the historical European investment manager’s published investment, investor-relations or corporate support platform, spanning venture/growth, private debt and dedicated portfolios. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.

New York startup accelerator and early-stage investor helping internationally minded technology founders build companies and expand between the United States and Asia. It combines capital, mentoring and market access, with investments including radiology data and AI company Quantivly.

Jane Tran co-founded Sixfold and serves as COO. She began in financial services at JPMorgan, subsequently worked in strategy at Marsh and MetLife, and became a founding-team member and COO at Unqork. Sixfold’s current biography also identifies her nonprofit mentorship and Womankind co-chair work. Lair East Labs independently confirms the same Sixfold/Unqork identity; its existingmentor affiliation remains preserved.

Venture capital firm founded in 2021 investing across healthcare technology and access to care. Its portfolio includes brain-health analytics, AI speech recognition, clinical imaging software, drug delivery and biotechnology platforms.

Angel investment group of entrepreneurs and executives backing seed-stage technology companies. Members invest, mentor founders and syndicate with other angels and institutional funds. Its portfolio includes radiology data and AI company Quantivly.

Early-stage venture capital firm backing Central and Eastern European and Ukrainian founders building global software businesses. It invests at pre-seed and seed stage, with portfolio companies spanning generative AI, workflow automation and healthcare data.

Develops small-molecule therapies for neurodegenerative diseases by restoring lysosomal function and autophagy and reducing toxic protein accumulation. Its research targets ALS, frontotemporal dementia and other neurological disorders.

Develops oral NLRP3 inflammasome inhibitors intended to reduce chronic inflammation in cardiovascular and neurological diseases. Its pipeline includes ruvonoflast for peripheral artery disease and brain-penetrant trabzanoflast. The company was formerly called NodThera.

Casey Cunningham is listed by Santé Ventures as Partner & Chief Scientific Officer. Joined 2008 after an academic oncology career and Mary Crowley Cancer Research Center leadership.

Clotilde Lagier-Tourenne is published by Arbor Biotechnologies as Scientific Advisory Board Member. Arbor lists this professional background: Associate Professor of Neurology, Harvard Medical School; Associate in Neuroscience, Massachusetts General Hospital; Healey Family ALS Endowed Chair for Research.

Geoff McDonough is publicly listed as an Atlas adviser and former CEO of Generation Bio in the current directory card. Its older undated biography still describes that CEO role in the present tense, so the card’s former qualification is retained. The biography describes previous leadership at Sobi and Genzyme, Harvard medical training, and undergraduate biology and philosophy at UNC. Existing company roles remain separate.

Jim Trenkle joined Novo Ventures (US) Inc. as a Partner in May 2022. Jim brings a background in R&D, commercialization, and early stage biotech investing and transactions. Prior to joining Novo, Jim was Head of Investments at Sanofi Ventures in Cambridge, MA, where he was responsible for a team making investments into private US-based therapeutics life science companies. Prior to Sanofi, Jim was Vice President of Investments with Pivotal bioVenture Partners in San Francisco. Jim began his career with Gilead Sciences where he held positions of increasing responsibility in medicinal chemistry, project and portfolio management, and commercial strategy, largely focused on hepatitis C and other liver diseases. Jim completed a B.S. in Honors Chemistry at University of Michigan, a Ph.D. in Organic Chemistry at Massachusetts Institute of Technology and holds an M.B.A. from University of California Berkeley, Haas School of Business.

Lin Ning is a senior associate supporting Dolby Family Ventures’ life-sciences portfolio, joining in2023. Her background includes a venture-partner role at Valkyrie Fund and neurobiology and bioengineering research. She studied neuron–microglia communication and developed non-invasive protein-imaging tools as a Stanford postdoctoral researcher. She earned a neuroscience PhD at the University of Helsinki and completed Stanford’s Ignite entrepreneurship programme.

Develops a cyclic aspiration system for removing blood clots during treatment of ischemic stroke, intended to restore blood flow more completely and reduce disability.

Brian R. Smith founded S3 Ventures and leads the firm as Managing Director. He previously founded and led Crossroads Systems through its 1999 IPO and worked in electrical engineering at IBM. His current portfolio work includes medical devices, enterprise software and AI-related companies. He studied electrical engineering at Cincinnati and Purdue. The existing RapidPulse board identity is the same person, independently corroborated by that issuer’s own biography.

Dennis McWilliams is listed by Santé Ventures as Managing Director. Medical technology entrepreneur who founded Apollo Endosurgery and SparkMed Advisors and co-founded Chrysalis BioTechnology.

Develops RNA-targeted therapeutics that modulate protein levels in the central nervous system to treat Huntington’s disease, Parkinson’s disease, Alzheimer’s disease and ALS. The company was previously called Transine Therapeutics.

Develops precision medicines for epilepsy and other neurological disorders, including Parkinson’s disease, using genetically validated targets and neuronal calcium channel inhibitors.

Partner and co-lead of Dementia Discovery Fund; molecular biotechnology researcher with prior venture investing experience at Wellington Partners and High-Tech Gründerfonds.

Heather Preston was publicly named by Arkuda Therapeutics as Board Member. Arkuda appointed her to its board in February2022 when Pivotal bioVenture Partners co-led the USD64M SeriesB. Her current own Harness biography identifies its board-chair role, over30years in healthcare, a medical degree from Oxford and earlier biotech-investment experience; the2022 Pivotal title is historical. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Andy Sack is published by Techstars as MD Emeritus (alumni directory). This is an alumni/advisory directory affiliation and does not establish a current full-time managing-director appointment. The current published directory verifies the named affiliation; exact appointment dates are undisclosed.

Nicole Glaros is published by Techstars as MD Emeritus (alumni directory). This is an alumni/advisory directory affiliation and does not establish a current full-time managing-director appointment. The current published directory verifies the named affiliation; exact appointment dates are undisclosed.

Semyon Dukach is published by Techstars as MD Emeritus (alumni directory). This is an alumni/advisory directory affiliation and does not establish a current full-time managing-director appointment. The current published directory verifies the named affiliation; exact appointment dates are undisclosed.

Canadian venture capital firm founded in 2021, making early investments in Black-led technology companies. Its portfolio includes AI-assisted cognitive rehabilitation company Moneta Health, drug-discovery simulation company Simmunome and agricultural AI company CropMind.

Developed AI personalization software for ecommerce recommendations and customer engagement. Netcore acquired the business and integrated its technology into its personalization products.

Develops robots for hazardous sewer and manhole cleaning, replacing manual sanitation work with remotely operated systems.

Built a marketplace for renting furniture, home furnishings and appliances to consumers seeking temporary access to household products.

Publishes news, research, data and analysis about Indian startups, venture funding and the technology economy.

Develops software-defined digital radio receiver technology for automotive and other broadcast applications. Visteon acquired the company in 2025.

Provides small consumer loans in India using data science and machine learning for credit assessment. The business was previously branded SmartCoin.

Provides a business banking platform combining accounts, payments, expense management and automated bookkeeping for small and medium businesses.

Provides pharmaceutical supply chain software for ordering, inventory management and commerce analytics, connecting pharmacies, distributors and manufacturers.

Develops AI cybersecurity software for enterprise threat detection, defense and incident response.